Late-Stage Clinical Study Readouts Biotech Investors Should Watch
Several drugmakers have important clinical trial updates on the way.
uniQure(QURE)
Nasdaq Global Select
QURE
$28.46
$0.22
0.8%
Price as of October 22, 2021, 4:00 p.m. ET
View Interactive QURE Charts
uniQure N.V.
Interactive Chart
Compare QURE Stock to Peers
| Symbol | Last Price | Market Cap | % Δ 1 Yr | % Δ 5 Yr |
|---|---|---|---|---|
|
QURE
uniQure
|
$28.46 | $1B | -34.5% | 308.3% |
|
EDIT |
$37.82 | $3B | 17.7% | 158.3% |
|
CRLBF |
$8.02 | $4B | 12.3% | |
|
IONS |
$30.44 | $4B | -35.2% | 12.1% |
|
BLUE |
$20.80 | $1B | -61.1% | -60.3% |
News & Analysis: uniQure
Why uniQure Stock Is Tanking Today
A clinical hold is weighing on the biotech's shares today.
uniQure Inks $2 Billion Licensing Deal With CSL Behring
Agreement licenses the rights for a promising hemophilia B gene therapy.
3 Stocks That Could Be the Next Biotech Buyouts
Here are the biotechs most likely to receive juicy buyout offers in 2020.
The Top Biotech Stocks to Watch Following ASH 2019
The potential to reshape treatment of blood cancer and disorders could mean big bucks for these companies.
Here's Why uniQure Is Rallying 13% Today
Investor optimism is surging following recent M&A in gene therapy.
What Drove uniQure 171% Higher in the First Half of 2019
Steady progress with experimental gene therapies gave investors reasons to cheer.
3 Biotechs That Have Doubled This Year (Acquisition Next?)
Good news has a way of attracting suitors.
2 More Gene Therapy Stocks on Big Pharma's Buyout Radar
Roche's big step into the gene-editing space will spark interest for these two stocks.
Here's Why Gene Therapy Stocks Are Soaring Today
Roche acquired Spark Therapeutics for a cool $4.8 billion, which sent peers soaring.
